BIOR Stock Price, Biora Therapeutics, Inc. Quote, Chart

Market Summary

USD0.62-0.02

Market Closed

-3.13%

BIOR Stock Price

View Fullscreen

BIOR RSI Chart

BIOR Valuation

Market Cap

19.4M

Price/Earnings (Trailing)

-0.16

Price/Sales (Trailing)

4.9K

EV/EBITDA

-0.04

Price/Free Cashflow

-0.4

BIOR Price/Sales (Trailing)

BIOR Profitability

EBT Margin

-3004825.00%

Return on Equity

-14.85%

Return on Assets

-397.61%

Free Cashflow Yield

-250.52%

BIOR Fundamentals

BIOR Revenue

Revenue (TTM)

4.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

BIOR Earnings

Earnings (TTM)

-124.1M

Earnings Growth (Yr)

-12.32%

Earnings Growth (Qtr)

79.02%

Breaking Down BIOR Revenue

Last 7 days

3.2%

Last 30 days

-46.7%

Last 90 days

-28.9%

Trailing 12 Months

-74.7%

How does BIOR drawdown profile look like?

BIOR Financial Health

Current Ratio

0.3

BIOR Investor Care

Shares Dilution (1Y)

155.62%

Diluted EPS (TTM)

-7.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	229.8K	154.5K	79.3K	4.0K
2022	1.2M	828.0K	726.0K	305.0K
2021	414.0K	666.0K	918.0K	1.2M
2020	113.3M	73.3M	36.8M	162.0K
2019	132.0M	136.0M	140.0M	144.0M
2018	0	0	0	128.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biora Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 15, 2024	mohanty aditya p.	acquired	-	-	819,000	chief executive officer
Feb 15, 2024	desparbes eric	acquired	-	-	325,000	chief financial officer
Feb 15, 2024	neumann clarke	acquired	-	-	230,000	see remarks
Sep 18, 2023	athyrium opportunities iii co-invest 1 lp	acquired	-	-	9,235,280	-
Aug 15, 2023	mohanty aditya p.	acquired	-	-	559,450	chief executive officer
Aug 15, 2023	mohanty aditya p.	sold (taxes)	-370,146	3.14	-117,881	chief executive officer
Aug 15, 2023	desparbes eric	acquired	-	-	219,650	chief financial officer
Aug 15, 2023	desparbes eric	sold (taxes)	-125,669	3.14	-40,022	chief financial officer
Aug 15, 2023	neumann clarke	acquired	-	-	210,175	see remarks
Aug 15, 2023	neumann clarke	sold (taxes)	-113,615	3.14	-36,183	see remarks

Which funds bought or sold BIOR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Leonard Rickey Investment Advisors P.L.L.C.	new	-	17,998	17,998	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	82.22	80,820	685,712	-%
Mar 04, 2024	TUCKER ASSET MANAGEMENT LLC	unchanged	-	-1.00	3.00	-%
Feb 26, 2024	Virtu Financial LLC	new	-	27,000	27,000	-%
Feb 15, 2024	BARCLAYS PLC	unchanged	-	-5,000	8,000	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-27,119	44,649	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-30,570	50,328	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	added	93.04	5,821	34,791	-%

Are Funds Buying or Selling BIOR?

Are funds buying BIOR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIOR

No. of Funds

Unveiling Biora Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 02, 2024	athyrium opportunities 2020 lp	35.4%	13,696,902	SC 13D/A
Feb 14, 2024	armistice capital, llc	3.80%	1,074,895	SC 13G/A
Dec 20, 2023	athyrium opportunities 2020 lp	34.9%	11,351,996	SC 13D/A
Sep 19, 2023	athyrium opportunities 2020 lp	34.0%	8,420,158	SC 13D/A
Mar 13, 2023	athyrium opportunities 2020 lp	16.4%	1,837,286	SC 13D/A
Feb 14, 2023	armistice capital, llc	5.70%	12,989,648	SC 13G
Jan 12, 2023	athyrium opportunities 2020 lp	14.2%	1,457,870	SC 13D/A
Nov 18, 2022	athyrium opportunities 2020 lp	14.6%	36,446,714	SC 13D/A

Recent SEC filings of Biora Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	EFFECT	EFFECT
Apr 12, 2024	PRE 14A	PRE 14A
Apr 08, 2024	S-3	S-3
Apr 02, 2024	SC 13D/A	13D - Major Acquisition
Apr 02, 2024	424B5	Prospectus Filed
Apr 02, 2024	424B5	Prospectus Filed
Apr 02, 2024	424B5	Prospectus Filed
Apr 02, 2024	424B5	Prospectus Filed
Apr 02, 2024	424B5	Prospectus Filed
Apr 02, 2024	424B5	Prospectus Filed

Biora Therapeutics, Inc. News

Latest updates

Biora Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-	-	-	2,000	8,000	14,000	80,000	104,000	107,000	435,000	182,000	463,000	167,000	106,000	8,686,000	17,266,000	16,828,000	20,476,000	18,772,000	57,230,000	47,507,000	-
Gross Profit	-	-	-	-	-	-	-	-	-	-627,500	182,000	463,000	2,292,000	7,261,500	56,000	-4,569,000	-9,742,000	-4,485,000	-6,225,000	31,117,000	-	-
Operating Expenses	-42.8%	13,344,000	23,321,000	14,936,000	15,546,000	13,790,000	13,967,000	14,314,000	20,015,000	20,594,000	30,743,000	36,116,000	31,631,000	16,859,500	30,722,000	26,483,000	42,784,000	44,488,000	48,616,000	45,415,000	-	-
S&GA Expenses	-43.4%	7,226,000	12,774,000	8,953,000	8,356,000	8,023,000	8,147,000	8,410,000	13,457,000	12,109,000	18,517,000	22,715,000	19,958,000	-5,223,000	1,563,000	1,547,000	14,436,000	13,378,000	15,263,000	14,680,000	-	-
R&D Expenses	-42.0%	6,118,000	10,547,000	5,983,000	7,190,000	5,767,000	5,820,000	5,904,000	6,558,000	8,485,000	12,226,000	13,401,000	11,673,000	11,225,000	13,043,000	12,234,000	11,240,000	14,609,000	17,080,000	16,463,000	-	-
EBITDA Margin	-Infinity%	-27,455	-	-264	-428	-322	-168	-179	-145	-137	-145	-195	-296	-896	-	-	-	-	-	-	-	-
Interest Expenses	-29.0%	1,840,000	2,592,000	2,703,000	2,680,000	-	2,773,000	2,772,000	2,760,000	2,186,000	3,458,000	3,502,000	3,520,000	2,677,000	2,457,000	2,489,000	2,302,000	2,327,000	2,321,000	2,282,000	-	-
Income Taxes	-9600.0%	-95,000	1,000	4,000	-	258,500	158,000	-837,000	1,000	-122,500	-	-	7,000	165,000	-	-1,000	-37,696,000	-712,000	-	-	-	-
Earnings Before Taxes	78.6%	-15,727,000	-73,453,000	-17,803,000	-	-13,210,000	-14,716,000	-6,834,000	-	-75,503,500	-36,874,000	-41,400,000	-32,264,000	-35,853,500	-33,142,000	-32,723,000	-54,848,000	-51,182,000	-57,133,000	-16,409,000	-	-
EBT Margin	-1898.1%	-30,048	-1,503	-340	-479	-361	-184	-193	-156	-149	-159	-214	-323	-	-	-	-	-	-	-	-	-
Net Income	79.0%	-15,413,000	-73,454,000	-17,807,000	-17,441,000	-13,722,000	-5,114,000	-5,513,000	-13,808,000	-92,874,000	-43,744,000	-78,531,000	-32,263,000	-75,528,000	-47,065,000	-52,783,000	-17,152,000	-50,476,000	-57,133,000	-16,409,000	-24,019,000	-
Net Income Margin	-1908.6%	-31,028	-1,544	-350	-181	-125	-161	-188	-192	-198	-250	-350	-501	-	-	-	-	-	-	-	-	-
Free Cashflow	-25.2%	-13,812,000	-11,035,000	-11,620,000	-12,116,000	-11,090,000	-9,969,000	-19,853,000	-24,297,000	-40,046,000	-43,192,000	-36,114,000	-48,989,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-10.1%	31.00	35.00	50.00	53.00	54.00	63.00	77.00	87.00	109	98.00	120	129	154	120	186	144	102	116
Current Assets	-0.9%	19.00	19.00	34.00	37.00	38.00	46.00	60.00	75.00	99.00	93.00	114	101	126	93.00	160	-	75.00	89.00
Cash Equivalents	21.0%	15.00	13.00	26.00	30.00	30.00	37.00	49.00	67.00	88.00	54.00	66.00	65.00	92.00	59.00	113	-	33.00	49.00
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	12.00	3.00	10.00	10.00	-	11.00	8.00
Net PPE	-6.5%	1.00	1.00	1.00	1.00	2.00	2.00	2.00	3.00	4.00	5.00	5.00	17.00	8.00	16.00	16.00	-	16.00	15.00
Goodwill	0%	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	-	-	6.00	6.00	6.00	6.00	-	6.00	6.00
Liabilities	-13.6%	133	153	171	158	156	160	173	180	194	275	260	254	261	180	204	195	186	153
Current Liabilities	-9.5%	63.00	70.00	38.00	25.00	23.00	27.00	41.00	47.00	62.00	103	86.00	80.00	73.00	87.00	95.00	-	100	78.00
Shareholder's Equity	-100.0%	-	836	760	758	744	735	731	728	723	538	531	467	453	424	420	299	283	124
Retained Earnings	-1.6%	-950	-935	-862	-844	-826	-813	-808	-802	-788	-695	-652	-573	-541	-465	-418	-	-348	-118
Additional Paid-In Capital	3.9%	869	836	760	758	744	735	731	728	723	538	531	467	453	424	420	-	283	124
Shares Outstanding	18.9%	28.00	23.00	13.00	12.00	9.00	7.00	7.00	7.00	7.00	3.00	3.00	2.00	2.00	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Cashflow From Operations	-24.6%	-13,746	-11,034	-11,622	-12,098	-11,001	-9,805	-19,639	-23,955	-40,046	-43,190	-35,686	-48,564	-70,679	-51,863	-12,316	-30,886	-45,845	-22,753	-	-
Share Based Compensation	-85.3%	1,546	10,531	2,014	2,384	2,166	2,139	1,446	2,053	2,402	3,935	3,459	2,166	1,796	2,163	2,228	2,057	592	631	-	-
Cashflow From Investing	247000.0%	2,469	-1.00	-19.00	-6.00	-72.00	-164	-214	-342	211	-432	-558	-463	-2,013	-1,304	-533	-1,094	-808	-1,164	-	-
Cashflow From Financing	588.7%	13,918	-2,848	7,630	12,081	4,516	-1,477	1,125	3,134	73,540	31,767	37,515	22,227	103,955	-834	116,017	10,584	53,645	24,762	-	-

BIOR Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 4	$ 305
Operating expenses:
Research and development	29,838	24,049
Selling, general and administrative	37,309	38,037
Total operating expenses	67,147	62,086
Loss from operations	(67,143)	(61,781)
Interest expense, net	(9,815)	(10,990)
Gain on warrant liabilities	18,004	20,904
Other (expense) income, net	(65,470)	2,617
Loss before income taxes	(124,424)	(49,250)
Income tax benefit	(90)	(420)
Loss from continuing operations	(124,334)	(48,830)
Gain from discontinued operations	219	10,673
Net loss	$ (124,115)	$ (38,157)
Net loss per share from continuing operations, basic	$ (7.88)	$ (6.4)
Net loss per share from continuing operations, diluted	(7.88)	(6.4)
Net gain per share from discontinued operations, basic	0.01	1.4
Net gain per share from discontinued operations, diluted	0.01	1.4
Net loss per share, basic	(7.87)	(5)
Net loss per share, diluted	$ (7.87)	$ (5)
Weighted average shares outstanding, basic	15,773,297	7,635,107
Weighted average shares outstanding, diluted	15,773,297	7,635,107

BIOR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash, cash equivalents and restricted cash	$ 15,211	$ 30,486
Income tax receivable	830	828
Prepaid expenses and other current assets	3,030	4,199
Current assets of disposal group held for sale	0	2,603
Total current assets	19,071	38,116
Property and equipment, net	1,156	1,654
Right-of-use assets	1,614	1,482
Other assets	3,302	6,201
Goodwill	6,072	6,072
Total assets	31,215	53,525
Current liabilities:
Accounts payable	2,843	3,606
Accrued expenses and other current liabilities	17,319	16,161
Warrant liabilities	40,834	3,538
Related party senior secured convertible notes, current portion	1,976	0
Total current liabilities	62,972	23,305
Convertible notes, net of unamortized discount of $259 and $4,914 as of December 31, 2023 and December 31,2022, respectively	9,966	127,811
Senior secured convertible notes, net of unamortized discount of $ 11,066 and $0 as of Devember 31, 2023 and December 31, 2022, respectively (Note 7)	14,591	0
Related party senior secured convertible notes net of unamortized discount of $7,951 and $0 as of December 31, 2023 and December 31, 2022, respectively (including future interest of $9,747and $0 as of December 31, 2023 and December 31, 2022, respectively) (Note 7)	19,179	0
Derivative liabilities	22,899	0
Other long-term liabilities	3,029	4,696
Total liabilities	132,636	155,812
Commitments and contingencies (Note 9)
Stockholders' deficit:
Common stock - $0.001 par value.164,000,000 shares authorized as of December 31,2023 and December 31,2022; 28,574,918 and 9,098,844 shares issued as of December 31,2023 and December 31,2022 respectively; 27,837,563 and 8,928,498 shares outstanding as of December 31,2023 and December 31,2022, respectively.	25	8
Additional paid-in capital	868,591	743,626
Accumulated deficit	(950,958)	(826,843)
Treasury stock - at cost; 737,355 and 170,346 shares of common stock as of December 31, 2023 and December 31, 2022, respectively	(19,079)	(19,078)
Total stockholders' deficit	(101,421)	(102,287)
Total liabilities and stockholders' deficit	$ 31,215	$ 53,525

About Biora Therapeutics, Inc.

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

CEO	Mr. Aditya P. Mohanty M.B.A.
WEBSITE	bioratherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	54

Biora Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Biora Therapeutics, Inc.? What does BIOR stand for in stocks?

BIOR is the stock ticker symbol of Biora Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biora Therapeutics, Inc. (BIOR)?

As of Tue Apr 23 2024, market cap of Biora Therapeutics, Inc. is 19.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIOR stock?

You can check BIOR's fair value in chart for subscribers.

What is the fair value of BIOR stock?

You can check BIOR's fair value in chart for subscribers. The fair value of Biora Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biora Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIOR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biora Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether BIOR is over valued or under valued. Whether Biora Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Biora Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIOR.

What is Biora Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, BIOR's PE ratio (Price to Earnings) is -0.16 and Price to Sales (PS) ratio is 4.85 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIOR PE ratio will change depending on the future growth rate expectations of investors.